Fig. 1.

Experimental design. At day 0, infarct model was created (white arrow). At 72 h, magnetic resonance imaging was performed (black arrow). Placebo, EV-CDCs or CDCs were intrapericardially administered at 72 h (grey arrow). Blood samples were collected at day 0 (Basal), 72 h (post-AMI) and 24 h after intrapericardial administration (post-therapy). Blood samples were used for flow cytometry analysis (triangles), hematology (squares) and biochemical analysis (rhombus)